This approach may improve patient safety and reduce the risk of delayed correction of hypokalemia during continuous insulin infusion therapy. However, a limitation of the clinical model developed in this study is the small number of cases and the lack of external validation. The gene discussed is INS; the disease is Hypokalemia.